<?xml version="1.0" encoding="UTF-8"?>
<p>This was a randomized, open‐label, multicenter, dose‐ranging, active‐controlled study of Rolontis versus pegfilgrastim in patients aged ≥18 years with breast cancer who were candidates for adjuvant or neoadjuvant treatment with TC chemotherapy (NCT01724866). Other key inclusion criteria included the willingness and ability to provide written informed consent; Eastern Cooperative Oncology Group (ECOG) performance status ≤2; adequate bone marrow function before the start of chemotherapy (ANC ≥1.5 × 10
 <sup>9</sup>/L, platelet count ≥100 × 10
 <sup>9</sup>/L, hemoglobin &gt;9 g/dL); creatinine ≤1.5× upper limit of normal (ULN); total bilirubin ≤1.5 mg/dL; aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ≤2.5 × ULN; and alkaline phosphatase ≤1.5 × ULN. Key exclusion criteria included a known sensitivity to 
 <italic>E coli</italic>‐derived products, L‐asparanginase, somatropin growth hormone, or recombinant interferon 
 <italic>α</italic>‐2b; an active infection or positive serology for human immunodeficiency virus, hepatitis B or hepatitis C; prior bone marrow or stem cell transplant; major surgery (except for breast surgery related to the patient's breast cancer diagnosis) within 4 weeks prior to enrollment; any other malignancy within 5 years prior to enrollment; pregnancy or breastfeeding; prolonged exposure to glucocorticosteroids and immunosuppressive agents; or dementia or significantly altered mental status that would prohibit the understanding and giving of informed consent or limit study compliance.
</p>
